gliclazide has been researched along with Fatty Liver in 1 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morieri, ML | 1 |
| Vitturi, N | 1 |
| Avogaro, A | 1 |
| Targher, G | 1 |
| Fadini, GP | 1 |
1 other study available for gliclazide and Fatty Liver
| Article | Year |
|---|---|
Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Fatty Liver; Female; Follow-U | 2021 |